{"value":{"id":1486570,"askingMemberId":1506,"askingMember":null,"house":"Commons","memberHasInterest":false,"dateTabled":"2022-07-05T00:00:00","dateForAnswer":"2022-07-11T00:00:00","uin":"31051","questionText":"To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of broadening the eligibility list for covid-19 antiviral treatments to include diabetics.","answeringBodyId":17,"answeringBodyName":"Department of Health and Social Care","isWithdrawn":false,"isNamedDay":true,"groupedQuestions":[],"answerIsHolding":false,"answerIsCorrection":false,"answeringMemberId":4447,"answeringMember":null,"correctingMemberId":null,"correctingMember":null,"dateAnswered":"2022-07-12T00:00:00","answerText":"<p>The Therapeutics Clinical Review Panel considers the latest evidence on the patients most at risk of adverse outcomes from COVID-19 and provides advice to the National Health Service on the appropriate patient cohorts for new therapies. Patients with diabetes were not identified in the initial patient cohorts currently receiving these treatments.</p><p>However, the PANORAMIC study is gathering further evidence on those patients who would benefit from oral antiviral treatments, including patients with type 1 and type 2 diabetes. The results from this study will inform clinical access policy for these treatments through the NHS, including any expansion of the current eligible patient cohorts. Any such changes would be proposed by the NHS and agreed by the United Kingdom Chief Medical Officers.</p>","originalAnswerText":"","comparableAnswerText":"","dateAnswerCorrected":null,"dateHoldingAnswer":"2022-07-11T00:00:00","attachmentCount":0,"heading":"Coronavirus: Medical Treatments","attachments":[],"groupedQuestionsDates":[]},"links":[{"rel":"self","href":"/Questions/1486570","method":"GET"}]}